NEW YORK (GenomeWeb News) – CVS Caremark the country’s largest pharmacy services provider, has decided to expand pharmacogenomic testing to its pharmacy benefit management customers to predict their responses to treatments for cancer, cardiovascular diseases, and HIV.

Generation Health, a company launched last year to help insurers, employers, and PBMs implement genetic testing with their systems, will help CVS Caremark put its pharmacogenomics testing programs in place, the companies said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.